Breaking News, Collaborations & Alliances

Lonza, Takeda Alliance Reaches Milestone

Takeda’s ALUNBRIG granted marketing authorization for ALK+ non-small cell lung cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza has reached a major milestone in its multiproduct partnership with Takeda Pharmaceutical Co. Takeda was granted marketing authorization by the European Commission for ALUNBRIG (brigatinib) as a monotherapy for the treatment of anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NLSC) previously treated with crizotinibthe.   Lonza Pharma & Biotech’s product development and manufacturing facility in Tampa, FL collaborated with Takeda on this cancer treatment...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters